Slingshot members are tracking this event:

Allergan (AGN) to complete Phase 3 study of of Vilazodone in Adolescent Patients With Major Depressive Disorder in summer 2016

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks


Additional Information

Additional Relevant Details Vilazodone also called Viibryd.  For the purposes of this study, adolescents are aged 12-17.  Allergan is conducting an additional Vilazodone study of 7-17 year olds set to finish in late 2017.  Forest Laboratories is a subsidiary of Allergan.
Slingshot Insights Explained
Catalyst Date
Occurred on:
Oct 06, 2016
Occurred Source:
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Phase 3 Study, Vilazodone, Major Depressive Disorder, Viibryd